Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Research & Development (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Research & Development for 10 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 54.81% to $1.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $12.4 million, a 4.25% decrease, with the full-year FY2024 number at $14.2 million, up 257.0% from a year prior.
  • Research & Development was $1.7 million for Q3 2025 at Rein Therapeutics, down from $4.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.9 million in Q1 2022 to a low of $22000.0 in Q3 2023.
  • A 5-year average of $3.3 million and a median of $3.7 million in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: tumbled 99.48% in 2023, then soared 16818.18% in 2024.
  • Rein Therapeutics' Research & Development stood at $4.6 million in 2021, then tumbled by 47.34% to $2.4 million in 2022, then dropped by 17.9% to $2.0 million in 2023, then soared by 68.46% to $3.3 million in 2024, then plummeted by 49.37% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Research & Development are $1.7 million (Q3 2025), $4.3 million (Q2 2025), and $3.1 million (Q1 2025).